Cite
HARVARD Citation
Daver, N. et al. (2022). Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti–PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute myeloid leukemia. Leukemia & lymphoma. 63 (11), pp. 2711-2714. [Online].